EISAI CO
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
- Conditions
- Biliary Tract Cancer
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06793709
A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures
- Conditions
- Partial-Onset SeizuresPrimary Generalized Tonic-clonic Seizures
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT06657378
- Locations
- 🇯🇵
1, Tokyo, Japan
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
- Conditions
- Alzheimer's Disease
- Interventions
- Other: No Intervention
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 5000
- Registration Number
- NCT06322667
- Locations
- 🇯🇵
Eisai trial site 1, Tokyo, Japan
🇯🇵Eisai trial site 2, Hiroshima, Japan
🇯🇵Eisai trial site 3, Kyoto, Japan
A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders
- Conditions
- Psychotic Disorders
- Interventions
- Other: No Intervention
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 579728
- Registration Number
- NCT05633108
- Locations
- 🇬🇧
Eisai Ltd. European Knowledge Centre, Hatfield, Hertfordshire, United Kingdom
A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- Other: PBO
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT05594589
- Locations
- 🇰🇷
Keimyung University Dongsan Hospital, Daegu-si, Korea, Republic of
🇰🇷Gacheon University Gil Medical Centre, Incheon, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05278663
- Locations
- 🇯🇵
Daido Clinic, Nagoya, Aichi, Japan
🇯🇵Tohoku University Hospital, Sendai, Miyagi, Japan
🇯🇵Hospital of the University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05278676
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, China
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 145
- Registration Number
- NCT05228158
- Locations
- 🇯🇵
Eisai Trial Site 216, Yatomi-shi, Aichi, Japan
🇯🇵Eisai Trial Site 206, Matsudo-shi, Chiba, Japan
🇯🇵Eisai Trial Site 240, Fukuoka-shi, Fukuoka, Japan
A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
- Conditions
- Gout
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 451
- Registration Number
- NCT05007392
- Locations
- 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳Yanbian University Hospital, Yanji, Jilin, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)
- Conditions
- Parkinson Disease
- Interventions
- Drug: Equfina
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 1088
- Registration Number
- NCT04724109
- Locations
- 🇯🇵
Eisai Trial Site 2, Osaka, Japan
🇯🇵Eisai Trial Site 1, Tokyo, Japan